Skip to content

IMMIX BIOPHARMA, INC.

IMMX

CIK 0001873835

← back to feed
Revenue (TTM)
$20M
Q1 Apr 2026
Net Income (TTM)
−$28.84M
−36.2% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$0.79
−17.1% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-149.3%
Q1 Apr 2026
Net Margin
-144.2%
Q1 Apr 2026
Free Cash Flow (TTM)
−$17.83M
Q1 Apr 2026
Cash
$79.25M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
54.41M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings